Imaginir works with mid-tier Korean beauty brands — export-capable, building US and EU presence in parallel, without an in-house regulatory or compliance function. If that's you, the compliance and claims decisions in front of you right now are probably more urgent than they feel.
Imaginir's work sits at the intersection of four things — read together, not as separate checklists:
How the brand's compliance posture shapes the customer's actual experience.
Building the engagement itself as a clear, well-sequenced process.
Cross-market judgment, coordinating the full path to shelf — Responsible Person, labeling, and packaging in the EU; registration and claims in the US — not just a single compliance check.
Reading claims and brand positioning together, not as two separate jobs.
In practice, that means claims and classification review isn't treated as a checklist exercise — it's read together with how the brand actually presents itself to Western buyers and customers, because those two things are more connected than most compliance-only vendors treat them.
Imaginir has no distribution or manufacturing relationship to protect, in either market. The review is about your brand's risk, not a channel partner's interest — which matters when the advice is "don't say that on your label" or "that ingredient needs to come out for the EU," not "buy more inventory."
Compliance is the most urgent, most concrete problem a growing brand faces when it looks at the US and EU markets — and it's a problem that can be diagnosed and acted on with just the brand as a client, before any buyer-side relationships exist. That's why it's the starting point, not the whole story: the same coordinating role extends across the rest of the path to shelf — Responsible Person and safety-assessment coordination in the EU, registration and claims review in the US, labeling, packaging, and eventually retail — rather than stopping at the first compliance check.
Imaginir is a new, solo advisory practice based in Seoul. Rather than point to a client roster that doesn't exist yet, the credibility here is meant to rest on the evidence: the FDA's and EU Safety Gate's own enforcement data, precedent cases like L’Oréal’s 2012 warning letter and the Lilial ban, and the specificity of the review itself. The first conversation — the free 20-minute gut-check — is designed to prove that directly, rather than ask you to take it on faith.
Start with a free 20-minute gut-check